WO2002070696A3 - Cd109 nucleic acid molecules polypeptides and methods of use - Google Patents

Cd109 nucleic acid molecules polypeptides and methods of use Download PDF

Info

Publication number
WO2002070696A3
WO2002070696A3 PCT/CA2002/000292 CA0200292W WO02070696A3 WO 2002070696 A3 WO2002070696 A3 WO 2002070696A3 CA 0200292 W CA0200292 W CA 0200292W WO 02070696 A3 WO02070696 A3 WO 02070696A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
methods
acid molecules
polypeptides
molecules polypeptides
Prior art date
Application number
PCT/CA2002/000292
Other languages
French (fr)
Other versions
WO2002070696A2 (en
Inventor
Andre Schuh
D Robert Sutherland
Original Assignee
Andre Schuh
D Robert Sutherland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andre Schuh, D Robert Sutherland filed Critical Andre Schuh
Priority to EP02704527A priority Critical patent/EP1409676A2/en
Priority to US10/471,345 priority patent/US7700316B2/en
Publication of WO2002070696A2 publication Critical patent/WO2002070696A2/en
Publication of WO2002070696A3 publication Critical patent/WO2002070696A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention is a CD109 nucleic acid molecule and its corresponding polypeptide. The invention also includes biologically functional equivalent nucleic acid molecules and polypeptides. The invention also relates to methods of using these nucleic acid sequences and polypeptides in medical diagnosis and treatment and in drug screening.
PCT/CA2002/000292 2001-03-07 2002-03-07 Cd109 nucleic acid molecules polypeptides and methods of use WO2002070696A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02704527A EP1409676A2 (en) 2001-03-07 2002-03-07 Cd109 nucleic acid molecules polypeptides and methods of use
US10/471,345 US7700316B2 (en) 2001-03-07 2002-03-07 CD109 nucleic acid molecules, polypeptides and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27381401P 2001-03-07 2001-03-07
US60/273,814 2001-03-07

Publications (2)

Publication Number Publication Date
WO2002070696A2 WO2002070696A2 (en) 2002-09-12
WO2002070696A3 true WO2002070696A3 (en) 2003-06-26

Family

ID=23045513

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/000292 WO2002070696A2 (en) 2001-03-07 2002-03-07 Cd109 nucleic acid molecules polypeptides and methods of use

Country Status (3)

Country Link
US (1) US7700316B2 (en)
EP (1) EP1409676A2 (en)
WO (1) WO2002070696A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1409725B1 (en) * 2001-03-07 2014-05-07 Andre Schuh Diagnosis and treatment of blood disorders
EP1409676A2 (en) 2001-03-07 2004-04-21 Andre Schuh Cd109 nucleic acid molecules polypeptides and methods of use
CA2445171A1 (en) * 2001-04-24 2002-10-31 Mcgill University A 150 kda tgf-beta 1 accessory receptor acting as a negative modulator of tgf-beta signaling
CA2585098C (en) 2004-10-22 2018-12-18 Revivicor, Inc. Porcine genomic kappa and lambda light chain sequences
DK2348827T3 (en) 2008-10-27 2015-07-20 Revivicor Inc IMMUNICIPLY COMPROMATED PETS
WO2010088778A1 (en) * 2009-02-09 2010-08-12 The Royal Institution For The Advancement Of Learning/Mcgill University Cd109 polypeptides and uses thereof for the treatment of skin cells
CN110295226A (en) * 2019-04-30 2019-10-01 山东省医药生物技术研究中心（山东省病毒研究所） Application of the CD109 as Diagnosis of Rheumatoid Arthritis marker and therapy target

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003557A1 (en) * 1989-08-29 1991-03-21 Novo Nordisk A/S Expression of alpha-macroglobulins
WO2002085942A2 (en) * 2001-04-24 2002-10-31 Mcgill University A 150 kda tgf-beta 1 accessory receptor acting as a negative modulator of tgf-beta signaling

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1161536A1 (en) * 1998-11-17 2001-12-12 Sagami Chemical Research Center Human proteins having hydrophobic domains and dnas encoding these proteins
EP1409676A2 (en) 2001-03-07 2004-04-21 Andre Schuh Cd109 nucleic acid molecules polypeptides and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003557A1 (en) * 1989-08-29 1991-03-21 Novo Nordisk A/S Expression of alpha-macroglobulins
WO2002085942A2 (en) * 2001-04-24 2002-10-31 Mcgill University A 150 kda tgf-beta 1 accessory receptor acting as a negative modulator of tgf-beta signaling

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 2 February 2001 (2001-02-02), "Hydrophobic domain protein cDNA HP02837 isolated from HT-1080 cells.", XP002236037, retrieved from EBI Database accession no. AAA62010 *
DATABASE EMBL [online] 2 February 2001 (2001-02-02), "Hydrophobic domain protein isolated from HT-1080 cells.", XP002236038, retrieved from EBI Database accession no. AAB12127 *
LIN MARTIN ET AL: "Cell surface antigen CD109 is a novel member of the alpha2 macroglobulin/C3, C4, C5 family of thioester-containing proteins.", BLOOD, vol. 99, no. 5, 1 March 2002 (2002-03-01), March 1, 2002, pages 1683 - 1691, XP002236036, ISSN: 0006-4971 *
MURRAY LESLEY J ET AL: "CD109 is expressed on a subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor cells.", EXPERIMENTAL HEMATOLOGY (CHARLOTTESVILLE), vol. 27, no. 8, August 1999 (1999-08-01), pages 1282 - 1294, XP002236034, ISSN: 0301-472X *
SCHUH ANDRE C ET AL: "A tyrosine703serine polymorphism of CD109 defines the Gov platelet alloantigens.", BLOOD, vol. 99, no. 5, 1 March 2002 (2002-03-01), March 1, 2002, pages 1692 - 1698, XP002236035, ISSN: 0006-4971 *
SCHUH ANDRE C ET AL: "Cell surface antigen CD109 is a novel member of the alpha2 macroglobulin/C3, C4, C5 family of thioester containing proteins.", BLOOD, vol. 98, no. 11 Part 2, 16 November 2001 (2001-11-16), 43rd Annual Meeting of the American Society of Hematology, Part 2;Orlando, Florida, USA; December 07-11, 2001, November 16, 2001, pages 50b, XP009008050, ISSN: 0006-4971 *
YU J F ET AL: "Comparison of the expression of CD109 and CD135 on CD34+ cells in human marrow, cord blood, and peripheral blood.", BLOOD, vol. 94, no. 10 SUPPL. 1 PART 2, 15 November 1999 (1999-11-15), Forty-first Annual Meeting of the American Society of Hematology;New Orleans, Louisiana, USA; December 3-7, 1999, pages 136b, XP009008362, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
US7700316B2 (en) 2010-04-20
WO2002070696A2 (en) 2002-09-12
EP1409676A2 (en) 2004-04-21
US20040266990A1 (en) 2004-12-30

Similar Documents

Publication Publication Date Title
AU7494701A (en) Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO1996034953A3 (en) Cd16-ii variants
AU2003284891A1 (en) A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
CA2257133A1 (en) Human dnase i hyperactive variants
EP2006298A3 (en) Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof
AU2002330215A1 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
ATE209684T1 (en) DNA SEQUENCES FOR MATRIX METAL PROTEASES, THEIR PREPARATION AND USE
EP2093298A3 (en) Compositions for diagnosis and therapy of diseases associated with aberrant expression of Futrins (R-Spondins)
ATE242005T1 (en) P277 PEPTIDE ANALOGUES, PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT AND DIAGNOSIS OF DIABETES
WO2002070696A3 (en) Cd109 nucleic acid molecules polypeptides and methods of use
WO2001042277A3 (en) Complementary peptide ligands generated from the human genome
WO2000069901A3 (en) Proteins with insulin-like activity useful in the treatment of diabetes
WO2004096856A3 (en) Secreted protein family
EP1702985A3 (en) Preferred segments of neural thread protein and methods of using the same
WO2001043693A3 (en) Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
WO2005000891A3 (en) Thrombopoietin proteins with improved properties
WO2000043510A3 (en) Ras activator nucleic acid molecules - guanine nucleotide releasing factor grf4, polypeptides and methods of use
CA2250433A1 (en) Human dnase ii
WO1998054209A3 (en) Human mast cell function-associated antigen (mafa) and uses thereof
AU2002328212A1 (en) Diagnosis and treatment of early pre-type 1 diabetes glial fibrillary acidic protein
GB0128763D0 (en) Nucleic acid molecules polypeptides and uses therefor including diagnosis and treatment of T-cell Leukaemia
WO2001094417A3 (en) Novel human seven transmembrane proteins and polynucleotides encoding the same
GB0128283D0 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of asthma
WO2002070560A3 (en) Nuclear hormone receptor ligand binding domain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2002704527

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002704527

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10471345

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP